About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Cancer Prevention in Women With a BRCA Mutation

NCT02225015·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Sophia Virani
CONTACT
416-351-3800 sophia.virani@wchospital.ca

Lead

Women's College Hospital

With

Canadian Institutes of Health Research (CIHR)
London Health Sciences Centre
Princess Margaret Hospital, Canada
H. Lee Moffitt Cancer Center and Research Institute

Age

35–70

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

Confirmed BRCA mutation
Age 35 to 70 years
No previous bilateral salpingo-oophorectomy
No previous or current ovarian cancer
At least 12 months since genetic testing or most recent contact by Narod follow-up study
Can speak and understand English

You may not be if

Currently receiving treatment for another cancer diagnosis
Pregnant
Given birth in the last 6 months
Booked surgical date for BSO

The record

StatusUnknown

PhasePhase 1

Taking part300

StartedJan 2015

UpdatedJun 9, 2016

Conditions

BRCA1 Gene Mutation BRCA2 Gene Mutation Breast Cancer Ovarian Cancer

Where3

London Regional Cancer Centre
London, Ontario, Canada
Women's College Hospital
Toronto, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada

Clareo Health | Cancer Prevention in Women With a BRCA Mutation